Another NHS partnership! But this time with HMR in primary care!
HMR will leverage AI-driven teledermatology to discharge patients with benign lesions earlier in the pathway before they reach secondary care. This will ultimately look to increase the conversion rate of patients with skin cancer into the Northern Care Alliance – where HMR refers into.
NCA is one of the UK’s largest centres for skin cancer and at present, the majority of patients HMR refers into the urgent suspected skin cancer pathway are later confirmed to have benign lesions. This means an unsustainable proportion of dermatology capacity at NCA has previously been taken up assessing these patients.
By implementing DERM in primary care at HMR, this should act as the foundation for freeing up dermatology capacity at NCA in secondary care – capacity that can be used to focus on seeing and treating patients with skin cancer.
Kylie Thornton, Transformation and Delivery Lead at General Manchester, ICB commented, “This partnership with Skin Analytics presents a real opportunity to detect skin cancer earlier in pathway, not only to relieve some of the burden on dermatology teams in secondary care, but free up capacity for treating patients who really need them. Together, we can enhance patient care through technology and I’m curious to understand the impact AI teledermatology can have at scale.”
See how DERM works in primary care: